Abacavir 600mg / lamivudina 300 mg (Kivexa®) en terapia de combinación antirretroviral para el tratamiento de la infección por el Virus de Inmunodeficiencia Humana en adultos y adolescentes mayores de 12 años de edad

Categoría Resumen estructurado de revisiones sistemáticas
RevistaHTA Database
Año 2012
Cargando información sobre las referencias

RECORD STATUS:

This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

CITATION:

All Wales Medicines Strategy Group (AWMSG). Abacavir 600mg/lamivudine 300mg (Kivexa®) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2008. 2008
Epistemonikos ID: 7143030044793e421b4f25dbbf3d810b8b65a307
First added on: Feb 06, 2015